Piper Sandler Reaffirms “Overweight” Rating for Karyopharm Therapeutics (NASDAQ:KPTI)

Karyopharm Therapeutics (NASDAQ:KPTI)‘s stock had its “overweight” rating restated by Piper Sandler in a research report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock, down from their prior price target of $15.00. Piper Sandler’s price objective would suggest a potential upside of 118.18% from the company’s previous close.

KPTI has been the topic of a number of other reports. Robert W. Baird lowered their price target on shares of Karyopharm Therapeutics from $25.00 to $21.00 and set an “outperform” rating on the stock in a research note on Thursday. HC Wainwright cut shares of Karyopharm Therapeutics from a “buy” rating to a “neutral” rating in a research note on Wednesday, July 16th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Karyopharm Therapeutics in a research note on Wednesday. Four research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $20.60.

Karyopharm Therapeutics Stock Down 5.5%

Shares of Karyopharm Therapeutics stock opened at $5.50 on Thursday. Karyopharm Therapeutics has a 52-week low of $3.51 and a 52-week high of $16.95. The company’s 50-day simple moving average is $6.00 and its 200-day simple moving average is $5.16. The firm has a market cap of $47.69 million, a price-to-earnings ratio of -0.38 and a beta of 0.34.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings results on Monday, August 11th. The company reported ($4.32) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($3.80) by ($0.52). The firm had revenue of $37.93 million for the quarter, compared to analyst estimates of $37.92 million. Karyopharm Therapeutics has set its FY 2025 guidance at EPS. Equities research analysts anticipate that Karyopharm Therapeutics will post -0.71 EPS for the current year.

Institutional Investors Weigh In On Karyopharm Therapeutics

A number of large investors have recently added to or reduced their stakes in KPTI. Two Sigma Investments LP grew its stake in Karyopharm Therapeutics by 60.3% in the 4th quarter. Two Sigma Investments LP now owns 137,786 shares of the company’s stock valued at $93,000 after acquiring an additional 51,856 shares during the last quarter. T. Rowe Price Investment Management Inc. acquired a new stake in Karyopharm Therapeutics in the 1st quarter valued at about $523,000. XTX Topco Ltd acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $56,000. Silverback Asset Management LLC grew its stake in Karyopharm Therapeutics by 40.0% in the 2nd quarter. Silverback Asset Management LLC now owns 70,000 shares of the company’s stock valued at $302,000 after acquiring an additional 20,000 shares during the last quarter. Finally, Baird Financial Group Inc. acquired a new stake in Karyopharm Therapeutics in the 2nd quarter valued at about $45,000. 66.44% of the stock is owned by institutional investors and hedge funds.

Karyopharm Therapeutics Company Profile

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).